Stephane Depil
Overview
Explore the profile of Stephane Depil including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1885
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Laurent P, Andre F, Bobard A, Deandreis D, Demaria S, Depil S, et al.
Oncoimmunology
. 2024 Dec;
14(1):2432726.
PMID: 39696783
Over the last decade, the annual Immunorad Conference, held under the joint auspicies of Gustave Roussy (Villejuif, France) and the Weill Cornell Medical College (New-York, USA) has aimed at exploring...
2.
Hidaoui D, Porquet A, Chelbi R, Bohm M, Polyzou A, Alcazer V, et al.
Commun Biol
. 2024 Nov;
7(1):1555.
PMID: 39578583
Chronic myelomonocytic leukemia (CMML) is a severe myeloid malignancy affecting the elderly, for which therapeutic options are limited. DNA hypomethylating agents (HMAs) provide transient responses, failing to eradicate the malignant...
3.
Chour M, Porteu F, Depil S, Alcazer V
Am J Hematol
. 2024 Oct;
100(1):116-130.
PMID: 39387681
Endogenous retroelements (EREs), which comprise half of the human genome, play a pivotal role in genome dynamics. Some EREs retained the ability to encode proteins, although most degenerated or served...
4.
Page A, Chuvin N, Valladeau-Guilemond J, Depil S
Cell Mol Immunol
. 2024 Mar;
21(4):315-331.
PMID: 38443448
Natural killer (NK) cell-based immunotherapies are attracting increasing interest in the field of cancer treatment. Early clinical trials have shown promising outcomes, alongside satisfactory product efficacy and safety. Recent developments...
5.
Ducarouge B, Redavid A, Victoor C, Chira R, Fonseca A, Hervieu M, et al.
Cell Death Differ
. 2023 Aug;
30(10):2201-2212.
PMID: 37633969
Drug resistance and cancer relapse represent significant therapeutic challenges after chemotherapy or immunotherapy, and a major limiting factor for long-term cancer survival. Netrin-1 was initially identified as a neuronal navigation...
6.
Baulu E, Gardet C, Chuvin N, Depil S
Sci Adv
. 2023 Feb;
9(7):eadf3700.
PMID: 36791198
T cell engineering has changed the landscape of cancer immunotherapy. Chimeric antigen receptor T cells have demonstrated a remarkable efficacy in the treatment of B cell malignancies in hematology. However,...
7.
Laurent P, Morel D, Meziani L, Depil S, Deutsch E
Oncoimmunology
. 2022 Dec;
12(1):2158013.
PMID: 36567802
Chimeric antigen receptor (CAR)-T cells have demonstrated significant improvements in the treatment of refractory B-cell malignancies that previously showed limited survival. In contrast, early-phase clinical studies targeting solid tumors have...
8.
Trad R, Warda W, Alcazer V, Neto Da Rocha M, Berceanu A, Nicod C, et al.
J Immunother Cancer
. 2022 Jul;
10(7).
PMID: 35803613
Background: Acute myeloid leukemia (AML) remains a very difficult disease to cure due to the persistence of leukemic stem cells (LSCs), which are resistant to different lines of chemotherapy and...
9.
Alcazer V, Bonaventura P, Tonon L, Michel E, Mutez V, Fabres C, et al.
Am J Hematol
. 2022 Jun;
97(9):1200-1214.
PMID: 35759575
Human endogenous retroviruses (HERVs) represent 8% of the human genome. The expression of HERVs and their immune impact have not been extensively studied in Acute Myeloid Leukemia (AML). In this...
10.
Mallet M, Boulos R, Alcazer V, Bonaventura P, Estornes Y, Chuvin N, et al.
Eur J Cancer
. 2022 Jun;
171:96-105.
PMID: 35714452
Background: Cancer vaccines and T-cell receptor (TCR) engineered T cells (Tg-T cell) represent two different therapeutic strategies that can target the same tumour epitopes. The first approach requires the induction...